{"id":447,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/ar\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","title":{"rendered":"\u0625\u0634\u0627\u0631\u0627\u062a Tirzepatide Dual GIP\/GLP-1: \u0634\u0631\u062d \u0627\u0644\u0622\u0644\u064a\u0629 \u0648\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629"},"content":{"rendered":"

Tirzepatide \u0639\u0628\u0627\u0631\u0629 \u0639\u0646 \u0628\u0628\u062a\u064a\u062f \u0645\u0624\u0633\u064a\u0644 \u062a\u0645 \u062a\u0635\u0645\u064a\u0645\u0647 \u0644\u062a\u0646\u0634\u064a\u0637 \u0643\u0644 \u0645\u0646 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u0628\u0628\u062a\u064a\u062f \u0627\u0644\u0623\u0646\u0633\u0648\u0644\u064a\u0646\u064a\u0629 \u0627\u0644\u0645\u0639\u062a\u0645\u062f\u0629 \u0639\u0644\u0649 \u0627\u0644\u062c\u0644\u0648\u0643\u0648\u0632 (GIP) \u0648\u0645\u0633\u062a\u0642\u0628\u0644 \u0627\u0644\u0628\u0628\u062a\u064a\u062f \u0627\u0644\u0634\u0628\u064a\u0647 \u0628\u0627\u0644\u062c\u0644\u0648\u0643\u0627\u062c\u0648\u0646 1 (GLP-1). \u0625\u0646 \u0641\u0647\u0645 \u0623\u0646 \u0639\u0644\u0645 \u0627\u0644\u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u0645\u0632\u062f\u0648\u062c \u064a\u062a\u0637\u0644\u0628 \u0641\u0635\u0644 \u0646\u0634\u0627\u0637 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0639\u0646 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0645\u0642\u0627\u0633\u0629 \u0641\u064a \u0645\u062c\u0645\u0648\u0639\u0627\u062a \u0633\u0643\u0627\u0646\u064a\u0629 \u0645\u062d\u062f\u062f\u0629.<\/p>

\u0627\u0644\u0648\u062c\u0628\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629<\/h2>
  • Tirzepatide \u0647\u0648 \u0646\u0627\u0647\u0636 \u0645\u0632\u062f\u0648\u062c \u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a GIP\/GLP-1\u060c \u0648\u0644\u064a\u0633 \"\u0646\u0627\u0647\u0636\u064b\u0627 \u062b\u0644\u0627\u062b\u064a\u064b\u0627\".<\/li>
  • \u0631\u0643\u0632\u062a \u062a\u062c\u0627\u0631\u0628 SURPASS \u0639\u0644\u0649 \u0646\u062a\u0627\u0626\u062c \u0645\u0631\u0636 \u0627\u0644\u0633\u0643\u0631\u064a \u0645\u0646 \u0627\u0644\u0646\u0648\u0639 2\u061b \u0631\u0643\u0632\u062a \u062a\u062c\u0627\u0631\u0628 SURMOUNT \u0639\u0644\u0649 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0645\u062a\u0639\u0644\u0642\u0629 \u0628\u0627\u0644\u0633\u0645\u0646\u0629.<\/li>
  • \u0644\u0627 \u062a\u062b\u0628\u062a \u0628\u064a\u0627\u0646\u0627\u062a \u0627\u0644\u0623\u062f\u0648\u064a\u0629 \u0627\u0644\u0646\u0647\u0627\u0626\u064a\u0629 \u0627\u0644\u0645\u0639\u062a\u0645\u062f\u0629 \u0645\u0646 FDA \u0627\u0644\u062c\u0648\u062f\u0629 \u0623\u0648 \u0627\u0644\u0633\u0644\u0627\u0645\u0629 \u0623\u0648 \u0627\u0644\u0641\u0639\u0627\u0644\u064a\u0629 \u0644\u0645\u0648\u0627\u062f \u0643\u062a\u0627\u0644\u0648\u062c \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0623\u0628\u062d\u0627\u062b \u063a\u064a\u0631 \u0630\u0627\u062a \u0627\u0644\u0635\u0644\u0629.<\/li><\/ul><\/div><\/div>
    \"\u0628\u0627\u062d\u062b
    \u0627\u0644\u062a\u0648\u0636\u064a\u062d \u0627\u0644\u062a\u062d\u0631\u064a\u0631\u064a \u0627\u0644\u0623\u0635\u0644\u064a \u0644\u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0628\u0628\u062a\u064a\u062f \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a. \u0625\u0646\u0647 \u0645\u0634\u0647\u062f \u0645\u062e\u062a\u0628\u0631\u064a \u0645\u0641\u0627\u0647\u064a\u0645\u064a\u060c \u0648\u0644\u064a\u0633 \u0635\u0648\u0631\u0629 \u0645\u0646\u062a\u062c \u0623\u0648 \u0639\u0644\u0627\u062c.<\/figcaption><\/figure>

    \u0645\u0627\u0630\u0627 \u062a\u0639\u0646\u064a \u0646\u0627\u0647\u0636\u0629 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a \u0627\u0644\u0645\u0632\u062f\u0648\u062c\u0629<\/h2>

    GIP \u0648GLP-1 \u0647\u0645\u0627 \u0646\u0638\u0627\u0645\u0627\u0646 \u0625\u0634\u0627\u0631\u0627\u062a \u0645\u0633\u062a\u062c\u064a\u0628\u0627\u0646 \u0644\u0644\u0645\u063a\u0630\u064a\u0627\u062a \u0645\u0639 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u0645\u062a\u062f\u0627\u062e\u0644\u0629 \u0648\u0645\u062a\u0645\u064a\u0632\u0629. \u062a\u0645 \u062a\u0635\u0645\u064a\u0645 Tirzepatide \u0643\u062c\u0632\u064a\u0621 \u0648\u0627\u062d\u062f \u0642\u0627\u062f\u0631 \u0639\u0644\u0649 \u062a\u0646\u0634\u064a\u0637 \u0643\u0644\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u064a\u0646. \u0627\u0644\u062a\u0623\u062b\u064a\u0631 \u0627\u0644\u0633\u0631\u064a\u0631\u064a \u0647\u0648 \u0646\u062a\u064a\u062c\u0629 \u0644\u0635\u064a\u062f\u0644\u0629 \u0627\u0644\u062c\u0632\u064a\u0621 \u0628\u0623\u0643\u0645\u0644\u0647 \u0648\u062a\u0639\u0631\u0636\u0647 \u0648\u0635\u064a\u0627\u063a\u062a\u0647. \u0648\u0644\u0627 \u064a\u0645\u0643\u0646 \u0627\u0633\u062a\u0646\u062a\u0627\u062c\u0647 \u0628\u0645\u062c\u0631\u062f \u0625\u0636\u0627\u0641\u0629 \u0648\u0635\u0641\u064a\u0646 \u0645\u0646\u0641\u0635\u0644\u064a\u0646 \u0644\u0644\u0645\u0633\u0627\u0631 \u0645\u0639\u064b\u0627.<\/p>

    \u062a\u062d\u062f\u062f \u0639\u0644\u0627\u0645\u0629 FDA \u0623\u0646 tirzepatide \u0647\u0648 \u0627\u0644\u0639\u0646\u0635\u0631 \u0627\u0644\u0646\u0634\u0637 \u0641\u064a \u0645\u0646\u062a\u062c\u0627\u062a \u0627\u0644\u0648\u0635\u0641\u0627\u062a \u0627\u0644\u0637\u0628\u064a\u0629 \u0627\u0644\u0645\u0639\u062a\u0645\u062f\u0629 \u0648\u064a\u0635\u0641 \u0627\u0644\u0645\u0624\u0634\u0631\u0627\u062a \u0648\u0627\u0644\u062a\u062d\u0630\u064a\u0631\u0627\u062a \u0648\u062a\u0641\u0627\u0635\u064a\u0644 \u0627\u0644\u062a\u0631\u0643\u064a\u0628\u0629 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u0645\u0646\u062a\u062c. \u062a\u0646\u062a\u0645\u064a \u0647\u0630\u0647 \u0627\u0644\u0628\u064a\u0627\u0646\u0627\u062a \u0625\u0644\u0649 \u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0646\u0647\u0627\u0626\u064a \u0627\u0644\u0645\u0639\u062a\u0645\u062f \u0627\u0644\u0645\u0630\u0643\u0648\u0631 \u0641\u064a \u0627\u0644\u0645\u0644\u0635\u0642.<\/p>

    \u0643\u064a\u0641\u064a\u0629 \u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629<\/h2>

    \u0643\u0627\u0646\u062a SURPASS-1 \u0639\u0628\u0627\u0631\u0629 \u0639\u0646 \u062a\u062c\u0631\u0628\u0629 3 \u0630\u0627\u062a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629 \u0639\u0644\u0649 \u0627\u0644\u0628\u0627\u0644\u063a\u064a\u0646 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u062f\u0627\u0621 \u0627\u0644\u0633\u0643\u0631\u064a \u0645\u0646 \u0627\u0644\u0646\u0648\u0639 2 \u0627\u0644\u0630\u064a\u0646 \u0644\u0627 \u064a\u062a\u0645 \u0627\u0644\u062a\u062d\u0643\u0645 \u0641\u064a\u0647 \u0628\u0634\u0643\u0644 \u0643\u0627\u0641\u064d \u0639\u0646 \u0637\u0631\u064a\u0642 \u0627\u0644\u0646\u0638\u0627\u0645 \u0627\u0644\u063a\u0630\u0627\u0626\u064a \u0648\u0645\u0645\u0627\u0631\u0633\u0629 \u0627\u0644\u0631\u064a\u0627\u0636\u0629. \u0648\u0643\u0627\u0646\u062a \u0646\u0642\u0637\u0629 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u0629 \u0647\u064a \u0627\u0644\u062a\u063a\u064a\u0631 \u0641\u064a \u0627\u0644\u0647\u064a\u0645\u0648\u062c\u0644\u0648\u0628\u064a\u0646 \u0627\u0644\u0633\u0643\u0631\u064a\u060c \u0645\u0639 \u0648\u0632\u0646 \u0627\u0644\u062c\u0633\u0645 \u0648\u0633\u0644\u0627\u0645\u062a\u0647 \u0645\u0646 \u0628\u064a\u0646 \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u0636\u0627\u0641\u064a\u0629. \u0642\u0627\u0645 SURMOUNT-1 \u0628\u062a\u0633\u062c\u064a\u0644 \u0627\u0644\u0628\u0627\u0644\u063a\u064a\u0646 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0627\u0644\u0633\u0645\u0646\u0629 \u0623\u0648 \u0632\u064a\u0627\u062f\u0629 \u0627\u0644\u0648\u0632\u0646 \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u062d\u0627\u0644\u0629 \u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u0648\u0632\u0646 \u0648\u0627\u0633\u062a\u062e\u062f\u0645 \u0627\u0644\u0646\u0633\u0628\u0629 \u0627\u0644\u0645\u0626\u0648\u064a\u0629 \u0644\u0644\u062a\u063a\u064a\u0631 \u0641\u064a \u0648\u0632\u0646 \u0627\u0644\u062c\u0633\u0645 \u0643\u0646\u0642\u0637\u0629 \u0646\u0647\u0627\u064a\u0629 \u0623\u0633\u0627\u0633\u064a\u0629.<\/p>

    \u064a\u0624\u062b\u0631 \u0639\u062f\u062f \u0627\u0644\u0633\u0643\u0627\u0646 \u0648\u0627\u0644\u0645\u0642\u0627\u0631\u0646\u0629 \u0648\u0645\u062f\u0629 \u0627\u0644\u0639\u0644\u0627\u062c \u0648\u0627\u0644\u062a\u0642\u062f\u064a\u0631 \u0648\u0645\u0639\u0627\u0644\u062c\u0629 \u0627\u0644\u062a\u0648\u0642\u0641 \u0639\u0644\u0649 \u0627\u0644\u062a\u0641\u0633\u064a\u0631. \u0644\u0627 \u064a\u0646\u0628\u063a\u064a \u0623\u0628\u062f\u064b\u0627 \u0641\u0635\u0644 \u0627\u0644\u0646\u0633\u0628\u0629 \u0627\u0644\u0645\u0626\u0648\u064a\u0629 \u0644\u0644\u0639\u0646\u0648\u0627\u0646 \u0639\u0646 \u0639\u0646\u0627\u0635\u0631 \u0627\u0644\u062a\u0635\u0645\u064a\u0645 \u062a\u0644\u0643.<\/p>

    SURPASS-1<\/strong>\u0627\u0644\u0645\u0631\u062d\u0644\u0629 3\u060c \u0645\u0631\u0636 \u0627\u0644\u0633\u0643\u0631\u064a \u0645\u0646 \u0627\u0644\u0646\u0648\u0639 2\u060c \u0646\u0642\u0637\u0629 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0644\u0644\u062a\u062d\u0643\u0645 \u0641\u064a \u0646\u0633\u0628\u0629 \u0627\u0644\u0633\u0643\u0631 \u0641\u064a \u0627\u0644\u062f\u0645<\/span><\/div>
    SURMOUNT-1<\/strong>\u0627\u0644\u0645\u0631\u062d\u0644\u0629 3\u060c \u0627\u0644\u0633\u0645\u0646\u0629\/\u0632\u064a\u0627\u062f\u0629 \u0627\u0644\u0648\u0632\u0646\u060c \u0646\u0642\u0637\u0629 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u064a\u0629 \u0644\u0648\u0632\u0646 \u0627\u0644\u062c\u0633\u0645<\/span><\/div>
    \u0627\u0644\u0633\u062c\u0644 \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a<\/strong>\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u0648\u0635\u0641 FDA \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u0645\u0646\u062a\u062c \u0648\u0644\u063a\u0629 \u0627\u0644\u0633\u0644\u0627\u0645\u0629<\/span><\/div><\/div><\/div>

    \u0644\u0645\u0627\u0630\u0627 \u064a\u0647\u0645 \u0627\u0644\u062a\u0643\u0627\u0641\u0624 \u0627\u0644\u0645\u0627\u062f\u064a<\/h2>

    \u062a\u0646\u0637\u0628\u0642 \u0646\u062a\u0627\u0626\u062c \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0639\u0644\u0649 \u0627\u0644\u062a\u062f\u062e\u0644 \u0627\u0644\u0645\u062f\u0631\u0648\u0633 \u0627\u0644\u0630\u064a \u062a\u0645 \u062a\u0635\u0646\u064a\u0639\u0647 \u0648\u0627\u0644\u062a\u062d\u0643\u0645 \u0641\u064a\u0647 \u0641\u064a \u0638\u0644 \u0638\u0631\u0648\u0641 \u062a\u0644\u0643 \u0627\u0644\u062a\u062c\u0631\u0628\u0629. \u0644\u0627 \u062a\u062b\u0628\u062a \u0647\u0648\u064a\u0629 \u0627\u0644\u062a\u0633\u0644\u0633\u0644 \u0648\u062d\u062f\u0647\u0627 \u0627\u0644\u062a\u0643\u0627\u0641\u0624 \u0641\u064a \u0627\u0644\u0646\u0642\u0627\u0621 \u0623\u0648 \u0627\u0644\u062a\u062c\u0645\u064a\u0639 \u0623\u0648 \u0627\u0644\u062a\u0646\u0627\u0642\u0636 \u0623\u0648 \u0627\u0644\u0639\u0642\u0645 \u0623\u0648 \u0627\u0644\u0639\u0628\u0621 \u0627\u0644\u062c\u0633\u064a\u0645\u064a \u0623\u0648 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0623\u0648 \u0627\u0644\u0627\u0633\u062a\u0642\u0631\u0627\u0631.<\/p>

    \u0628\u0627\u0644\u0646\u0633\u0628\u0629 \u0644\u0644\u0645\u0648\u0627\u062f \u0627\u0644\u0628\u062d\u062b\u064a\u0629 \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c\u060c \u064a\u062c\u0628 \u0639\u0644\u0649 \u0627\u0644\u0628\u0627\u062d\u062b\u064a\u0646 \u0627\u0644\u0627\u0639\u062a\u0645\u0627\u062f \u0639\u0644\u0649 \u0627\u0644\u0645\u0648\u0627\u0635\u0641\u0627\u062a \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0627\u0644\u0645\u0646\u062a\u062c \u0648\u0648\u062b\u0627\u0626\u0642 \u0627\u0644\u062f\u0641\u0639\u0629. \u0644\u0627 \u064a\u0646\u0628\u063a\u064a \u0646\u0642\u0644 \u0627\u0644\u0645\u0637\u0627\u0644\u0628\u0627\u062a \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u0646 \u062f\u0648\u0627\u0621 \u0645\u0639\u062a\u0645\u062f \u0625\u0644\u0649 \u0635\u0641\u062d\u0629 \u0645\u0646\u062a\u062c \u0644\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0628\u062d\u062b\u064a.<\/p>","protected":false},"excerpt":{"rendered":"

    \u062a\u0641\u0633\u064a\u0631 \u0645\u062f\u0639\u0648\u0645 \u0628\u0627\u0644\u0623\u062f\u0644\u0629 \u062d\u0648\u0644 \u0646\u0627\u0647\u0636\u0629 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a tirzepatide \u0627\u0644\u0645\u0632\u062f\u0648\u062c\u0629 \u0648\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0642\u0627\u0633\u0629 \u0641\u064a \u062a\u062c\u0627\u0631\u0628 SURPASS \u0648SURMOUNT\u060c \u0645\u0639 \u062d\u062f\u0648\u062f \u0648\u0627\u0636\u062d\u0629 \u0644\u062a\u0637\u0628\u064a\u0642 \u0628\u064a\u0627\u0646\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0621 \u0639\u0644\u0649 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c.<\/p>","protected":false},"author":1,"featured_media":617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"370","pim_article_type":"Clinical evidence explainer","pim_evidence_level":"Randomized phase 3 trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"SURPASS-1 randomized phase 3 trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34186022\/\",\"note\":\"Primary clinical trial record; PMID 34186022.\"},{\"title\":\"SURMOUNT-1 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\",\"note\":\"Primary clinical trial record; PMID 35658024.\"},{\"title\":\"FDA prescribing information for Mounjaro (tirzepatide)\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf\",\"note\":\"Approved-finished-product regulatory record.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-447","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\nTirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/ar\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\" \/>\n<meta property=\"og:description\" content=\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/ar\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"\u062f\u0642\u064a\u0642\u062a\u0627\u0646\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\",\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tirzepatide Dual GIP\\\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/ar\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"\u062a\u0634\u0648\u064a\u0631 Tirzepatide \u0627\u0644\u0645\u0632\u062f\u0648\u062c GIP\/GLP-1: \u0634\u0631\u062d \u0627\u0644\u0622\u0644\u064a\u0629 \u0648\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629 - NHD","description":"\u062a\u0641\u0633\u064a\u0631 \u0645\u062f\u0639\u0648\u0645 \u0628\u0627\u0644\u0623\u062f\u0644\u0629 \u062d\u0648\u0644 \u0646\u0627\u0647\u0636\u0629 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a tirzepatide \u0627\u0644\u0645\u0632\u062f\u0648\u062c\u0629 \u0648\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0642\u0627\u0633\u0629 \u0641\u064a \u062a\u062c\u0627\u0631\u0628 SURPASS \u0648SURMOUNT\u060c \u0645\u0639 \u062d\u062f\u0648\u062f \u0648\u0627\u0636\u062d\u0629 \u0644\u062a\u0637\u0628\u064a\u0642 \u0628\u064a\u0627\u0646\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0621 \u0639\u0644\u0649 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/ar\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_locale":"ar_AR","og_type":"article","og_title":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","og_description":"An evidence-led explanation of tirzepatide dual receptor agonism and the endpoints measured in SURPASS and SURMOUNT trials, with clear limits on applying drug data to catalog materials.","og_url":"https:\/\/nhdbio.com\/ar\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"NHD Technical Team","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"\u062f\u0642\u064a\u0642\u062a\u0627\u0646"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"ar","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","url":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/","name":"\u062a\u0634\u0648\u064a\u0631 Tirzepatide \u0627\u0644\u0645\u0632\u062f\u0648\u062c GIP\/GLP-1: \u0634\u0631\u062d \u0627\u0644\u0622\u0644\u064a\u0629 \u0648\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a\u0629 - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"\u062a\u0641\u0633\u064a\u0631 \u0645\u062f\u0639\u0648\u0645 \u0628\u0627\u0644\u0623\u062f\u0644\u0629 \u062d\u0648\u0644 \u0646\u0627\u0647\u0636\u0629 \u0645\u0633\u062a\u0642\u0628\u0644\u0627\u062a tirzepatide \u0627\u0644\u0645\u0632\u062f\u0648\u062c\u0629 \u0648\u0646\u0642\u0627\u0637 \u0627\u0644\u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0642\u0627\u0633\u0629 \u0641\u064a \u062a\u062c\u0627\u0631\u0628 SURPASS \u0648SURMOUNT\u060c \u0645\u0639 \u062d\u062f\u0648\u062f \u0648\u0627\u0636\u062d\u0629 \u0644\u062a\u0637\u0628\u064a\u0642 \u0628\u064a\u0627\u0646\u0627\u062a \u0627\u0644\u062f\u0648\u0627\u0621 \u0639\u0644\u0649 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tirzepatide-dual-gip-glp-1-mechanism-trial-endpoints\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tirzepatide Dual GIP\/GLP-1 Signaling: Mechanism and Trial Endpoints Explained"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"\u0645\u0648\u0627\u062f \u062e\u0627\u0645 \u0628\u0628\u062a\u064a\u062f\u064a\u0629 \u0648\u062a\u062e\u0644\u064a\u0642 \u0627\u0644\u0628\u0628\u062a\u064a\u062f\u0627\u062a \u062d\u0633\u0628 \u0627\u0644\u0637\u0644\u0628","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u0627\u0644\u0641\u0631\u064a\u0642 \u0627\u0644\u0641\u0646\u064a NHD","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"\u064a\u062d\u062a\u0641\u0638 \u0641\u0631\u064a\u0642 NHD \u0627\u0644\u0641\u0646\u064a \u0628\u0648\u062b\u0627\u0626\u0642 \u0643\u062a\u0627\u0644\u0648\u062c \u0627\u0644\u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0628\u062d\u062b\u064a \u0648\u0645\u0644\u062e\u0635\u0627\u062a \u0627\u0644\u0623\u062f\u0644\u0629. \u062a\u0631\u062a\u0628\u0637 \u0627\u0644\u0645\u0642\u0627\u0644\u0627\u062a \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0628\u0627\u0644\u0623\u0648\u0631\u0627\u0642 \u0627\u0644\u062a\u064a \u062a\u0645\u062a \u0645\u0631\u0627\u062c\u0639\u062a\u0647\u0627 \u0645\u0646 \u0642\u0628\u0644 \u0627\u0644\u0646\u0638\u0631\u0627\u0621\u060c \u0648\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0648\u0627\u0644\u0633\u062c\u0644\u0627\u062a \u0627\u0644\u062a\u0646\u0638\u064a\u0645\u064a\u0629\u060c \u0648\u062a\u062d\u062a\u0641\u0638 \u0628\u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0641\u0627\u0631\u063a\u0629 \u0648\u0642\u064a\u0648\u062f \u0627\u0644\u062f\u0631\u0627\u0633\u0629\u060c \u0648\u062a\u0645\u064a\u0632 \u0627\u0644\u062a\u062f\u062e\u0644\u0627\u062a \u0627\u0644\u0645\u0646\u0634\u0648\u0631\u0629 \u0639\u0646 \u0645\u0648\u0627\u062f \u0627\u0644\u0643\u062a\u0627\u0644\u0648\u062c. \u064a\u0645\u0643\u0646 \u0627\u0633\u062a\u062e\u062f\u0627\u0645 \u0627\u0644\u0635\u064a\u0627\u063a\u0629 \u0628\u0645\u0633\u0627\u0639\u062f\u0629 AI \u0644\u0644\u0647\u064a\u0643\u0644\u061b \u062a\u0638\u0644 \u0631\u0648\u0627\u0628\u0637 \u0627\u0644\u0645\u0635\u062f\u0631 \u0648\u062d\u062f\u0648\u062f \u0627\u0644\u0623\u062f\u0644\u0629 \u0645\u0631\u0626\u064a\u0629. \u0647\u0630\u0627 \u0627\u0644\u0639\u0645\u0644 \u0644\u064a\u0633 \u0645\u0631\u0627\u062c\u0639\u0629 \u0623\u0642\u0631\u0627\u0646 \u0645\u0633\u062a\u0642\u0644\u0629 \u0623\u0648 \u0646\u0635\u064a\u062d\u0629 \u0637\u0628\u064a\u0629.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/ar\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/447","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/comments?post=447"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/447\/revisions"}],"predecessor-version":[{"id":524,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/posts\/447\/revisions\/524"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/media?parent=447"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/categories?post=447"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/ar\/wp-json\/wp\/v2\/tags?post=447"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}